TipRanks
Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh (BR:GILD34)
:GILD34
Brazil Market
GILD34
Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh
RESEARCH TOOLSreports

Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh (GILD34) Price & Analysis

― Followers

GILD34 Stock Chart & Stats

R$63.60
R$0.98(1.56%)
―
--
Day’s Range― - ―
52-Week Range<R$0.01 - R$73.80
Previous CloseN/A
VolumeN/A
Average Volume (3M)537.00
Market Cap
R$934.71B
Enterprise ValueR$920.58K
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.22
Next Earnings
Oct 22, 2026
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding14,879,462,000
10 Day Avg. Volume489
30 Day Avg. Volume537
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A

Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh News

Gilead announces expanded scope of licensing agreements for lenacapavir
Gilead announces expanded scope of licensing agreements for lenacapavir
Gilead (GILD) Sciences announced that it has expanded the scope of its six royalty-free voluntary licensing agreements for...
20h ago
GILD
Gilead announces agreement with PAHO for lenacapavir access
Gilead announces agreement with PAHO for lenacapavir access
Gilead (GILD) Sciences announced a new agreement with the Pan American Health Organization, or PAHO, to accelerate access...
2d ago
GILD
Gilead price target raised to $175 from $155 at HSBC
Gilead price target raised to $175 from $155 at HSBC
HSBC analyst Morten Herholdt raised the firm’s price target on Gilead (GILD) to $175 from $155 and keeps...
7d ago
GILD
Assembly Biosciences exercises profit share option with Gilead for HSV program
Assembly Biosciences exercises profit share option with Gilead for HSV program
Assembly Biosciences (ASMB) announced it has exercised its option to share 40% of the development costs and profits...
9d ago
ASMB
GILD
Gilead’s Bixlenvo approved by FDA for virologically suppressed adults with HIV
Gilead’s Bixlenvo approved by FDA for virologically suppressed adults with HIV
Gilead (GILD) Sciences announced that the FDA approved Bixlenvo – bictegravir 75 mg/lenacapavir 50 mg -, the smallest...
20d ago
GILD
Lakefront Biotherapeutics granted orphan drug designation for gamgertamig
Lakefront Biotherapeutics granted orphan drug designation for gamgertamig
Lakefront Biotherapeutic (LKFT) announced that the FDA has granted orphan drug designation to gamgertamig for the treatment of...
24d ago
GILD
LKFT
Gilead says EC grants marketing authorization for Trodelvy/Keytruda combination
Gilead says EC grants marketing authorization for Trodelvy/Keytruda combination
Gilead (GILD) Sciences announced that the European Commission has granted marketing authorization for Trodelvy in combination with Keytruda...
24d ago
MRK
GILD
MacroGenics receives $10M milestone after Gilead exercises license option
MacroGenics receives $10M milestone after Gilead exercises license option
MacroGenics (MGNX) announced that Gilead Sciences (GILD) has exercised its option to obtain an exclusive license for a...
1M ago
GILD
MGNX
Gilead: Strong HIV and Oncology Growth Underpins Reiterated Buy Rating and Unchanged $165 Price Target
Gilead: Strong HIV and Oncology Growth Underpins Reiterated Buy Rating and Unchanged $165 Price Target
Michael Okunewitch, an analyst from Maxim Group, reiterated the Buy rating on Gilead Sciences. The associated price target...
1M ago
GILD
Gilead files automatic mixed securities shelf
Gilead files automatic mixed securities shelf
17:08 EDT Gilead (GILD) files automatic mixed securities shelf Published first on TheFly – the ultimate source for...
1M ago
GILD
Gilead price target lowered to $150 from $156 at Truist
Gilead price target lowered to $150 from $156 at Truist
Truist lowered the firm’s price target on Gilead (GILD) to $150 from $156 and keeps a Buy rating...
1M ago
GILD
Gilead: Buy Rating Reaffirmed on Strong Fundamentals and HIV Franchise Momentum; $165 Price Target Maintained
Gilead: Buy Rating Reaffirmed on Strong Fundamentals and HIV Franchise Momentum; $165 Price Target Maintained
Analyst Terence Flynn of Morgan Stanley maintained a Buy rating on Gilead Sciences, retaining the price target of...
1M ago
GILD
Gilead Buy Rating Reaffirmed on Strong HIV-Driven Growth and Raised Revenue Outlook; $170 Price Target Maintained
Gilead Buy Rating Reaffirmed on Strong HIV-Driven Growth and Raised Revenue Outlook; $170 Price Target Maintained
Needham analyst Joseph Stringer reiterated a Buy rating on Gilead Sciences today and set a price target of...
1M ago
GILD
Gilead Sciences: Strong Core Performance and Upgraded HIV Outlook Underpin Buy Rating and Earnings Power
Gilead Sciences: Strong Core Performance and Upgraded HIV Outlook Underpin Buy Rating and Earnings Power
In a report released yesterday, Tyler Van Buren from TD Cowen maintained a Buy rating on Gilead Sciences,...
1M ago
GILD

GILD34 FAQ

What was Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh’s price range in the past 12 months?
Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh lowest stock price was <R$0.01 and its highest was R$73.80 in the past 12 months.
    What is Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh’s market cap?
    Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh’s market cap is R$934.71B.
      When is Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh’s upcoming earnings report date?
      Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh’s upcoming earnings report date is Oct 22, 2026 which is in 35 days.
        How were Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh’s earnings last quarter?
        Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh released its earnings results on Aug 04, 2026. The company reported -R$0.004 earnings per share for the quarter.
          Is Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh overvalued?
          According to Wall Street analysts Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh pay dividends?
            Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh does not currently pay dividends.
            What is Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh’s EPS estimate?
            Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh have?
            Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh has 14,879,462,000 shares outstanding.
              What happened to Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh’s price movement after its last earnings report?
              Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh reported an EPS of -R$0.004 in its last earnings report. Following the earnings report the stock price went down -2.749%.
                Which hedge fund is a major shareholder of Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh?
                Currently, no hedge funds are holding shares in BR:GILD34
                What is the TipRanks Smart Score and how is it calculated?
                Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                  Gilead Sciences, Inc Unsponsored Brazilian Depository Receipt Repr 1/2 Sh (GILD34) Earnings & Revenues

                  Historic Earnings Reports

                  Technical Analysis

                  Overall Consensus
                  Strong Buy
                  17Bullish
                  5Neutral
                  0Bearish
                  Bullish
                  Neutral
                  Bearish
                  Overall Consensus
                  17
                  5
                  0
                  Technical Analysis
                  5
                  5
                  0
                  Moving Averages
                  12
                  0
                  0
                  Technical Analysis >
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  AMGN34
                  Amgen Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.03571 Sh
                  ―
                  ―
                  BMYB34
                  Bristol-Myers Squibb Company Shs Unsponsored Brazilian Depository Receipt Repr 1 Sh
                  ―
                  ―
                  G1SK34
                  GSK PLC ADR Unsponsored Brazilian Depositary Receipt Repr 0.2 ADR
                  ―
                  ―
                  PFIZ34
                  Pfizer Inc Shs Unsponsored Brazilian Depository Receipts Repr 0.25 Sh
                  ―
                  ―
                  VRTX34
                  Vertex Pharmaceuticals Incorporated Shs Unsponsored Brazilian Depository Receipt Repr 1/4 Sh
                  ―
                  ―
                  Compare BR:GILD34 Stocks >
                  Popular Stocks